Cargando…

Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

Molecularly targeted therapies, directed against the features of a given tumor, have allowed for a personalized approach to the treatment of advanced non-small-cell lung cancer (NSCLC). The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jotte, Robert M, Spigel, David R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673988/ https://www.ncbi.nlm.nih.gov/pubmed/26310719 http://dx.doi.org/10.1002/cam4.506

Ejemplares similares

Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients
por: Li, Wen‐Qian, et al.
Publicado: (2021)

Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer
por: Jiang, Shirley Xue, et al.
Publicado: (2019)

Epidermal growth factor receptor and notch signaling in non‐small‐cell lung cancer
por: Pancewicz‐Wojtkiewicz, Joanna
Publicado: (2016)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
por: Li, Junjie, et al.
Publicado: (2019)

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
por: Cortot, Alexis B., et al.
Publicado: (2014)

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer
por: Yu, Limeng, et al.
Publicado: (2023)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

Next‐generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non‐small cell lung cancer
por: Zhang, Yujun, et al.
Publicado: (2021)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
por: Yamaoka, Toshimitsu, et al.
Publicado: (2017)

Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma
por: Kawana, Sachiko, et al.
Publicado: (2020)

The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Akazawa, Yuki, et al.
Publicado: (2023)

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2019)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Justin A., et al.
Publicado: (2020)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
por: Chen, Chen, et al.
Publicado: (2020)

Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations
por: Tan, Pui San, et al.
Publicado: (2017)

Profiling of circulating tumor DNA in plasma of non‐small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells
por: Garcia, Jessica, et al.
Publicado: (2019)

HER2 targeting near‐infrared photoimmunotherapy for a CDDP‐resistant small‐cell lung cancer
por: Takahashi, Kazuomi, et al.
Publicado: (2021)

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
por: Shiroyama, Takayuki, et al.
Publicado: (2017)

Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2‐positive breast cancer: a meta‐analysis of randomized controlled trials
por: Xin, Yong, et al.
Publicado: (2016)

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
por: Verschraegen, Claire F, et al.
Publicado: (2020)

An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
por: Bhateja, Priyanka, et al.
Publicado: (2019)

Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer
por: McCann, Katy, et al.
Publicado: (2022)

Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer
por: Huang, Shu-Mei, et al.
Publicado: (2017)

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
por: Bacchi, Carlos E., et al.
Publicado: (2012)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape
por: Xia, Wei, et al.
Publicado: (2019)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2020)

Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer
por: Zhao, Qian, et al.
Publicado: (2021)

Impact of somatic mutations on prognosis in resected non‐small‐cell lung cancer: The Japan Molecular Epidemiology for lung cancer study
por: Tamiya, Akihiro, et al.
Publicado: (2020)

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
por: Kobayashi, Kunihiko, et al.
Publicado: (2013)

Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation
por: Ceresa, Brian P., et al.
Publicado: (2008)

Epidermal growth factor receptors in non-small cell lung cancer.
por: Veale, D., et al.
Publicado: (1987)

Trends in phase III randomized controlled clinical trials on the treatment of advanced non‐small‐cell lung cancer
por: Fernández‐López, Cristina, et al.
Publicado: (2016)

Optimal surgical timing and radiotherapy dose for trimodality therapy in locally advanced non‐small cell lung cancer
por: Han, James E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h6fd2amfni2q4d891lp6uplvcm